Study #2020-1312
Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Kinase Inhibitor Therapy and Platinum-based Chemotherapy (TROPION-Lung05) (Phase 2 Study
MD Anderson Study Status
Not Accepting
Treatment Agent
DS-1062a
Description
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer
Study phase:
Phase II
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-888-994-0731
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.